JBiSE  Vol.8 No.3 , March 2015
Involvement of Autoimmune Diseases in the Pathogenesis of Chronic Immune Thrombocytopenic Purpura
ABSTRACT
Chronic immune thrombocytopenic purpura (ITP) is a condition based on an immune-mediated mechanism that determines the premature hyperdestruction of the thrombocytes in peripheral blood, as well as their deficient synthesis at the level of the bone marrow. The chronic immune purpura could be of primary, idiopathic cause, as well as of secondary cause, occurring in the context of other pathologies. The characteristic of the primary form of the disease is the presence of isolated thrombocytopenia, defined by a platelet count under 100,000/mm3 in peripheral blood, in the absence of supporting causes for thrombocytopenia. In the secondary form of the disease, the decreased platelet count is due to associated pathologies involving an immune mechanism, responsible for the occurrence of thrombocytopenia. This study aims to emphasize the involvement of autoimmune diseases, such as systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid polyarthritis or antiphospholipid syndrome in the pathogenesis of secondary thrombocytopenia. Furthermore, the study was conducted on a sample of 40 patients, divided into two groups: The first group comprising asymptomatic patients diagnosed with thrombocytopenia following routine tests, and the second group comprising patients with hemorrhagiparous symptomatology (petechiae, ecchymoses, epistaxis, gingivorrhagia), who went to the doctor in order to determine the etiology of the hemorrhagiparous syndrome. The average value of the thrombocytopenia of the patients included in the study was of 60.20 ± 19.75 × 103/μL. Laboratory investigations performed in order to establish the etiology of thrombocytopenia showed that 80% of patients presented positive antiplatelet antibodies. Moreover, 20% of the patients in the study showed positive anti-double-stranded DNA, 20% were identified with IgG anticardiolipin antibodies, while antinuclear antibodies were present in 10% of the patients.

Cite this paper
Mocanu, M. , Bădescu, M. , Ciocoiu, M. , Bădescu, C. , Iancu, C. and Bădulescu, O. (2015) Involvement of Autoimmune Diseases in the Pathogenesis of Chronic Immune Thrombocytopenic Purpura. Journal of Biomedical Science and Engineering, 8, 142-148. doi: 10.4236/jbise.2015.83014.
References
[1]   Danaila, C. (2004) Hematologie Generala.

[2]   Braunwald, Fauci, Kasper, Hauser, Longo and Jameson (2002) Principios de Medicina Interna. 15th Edition, McGraw Hill, New York, 882-884.

[3]   McMillan, R. (2007) The Pathogenesis of Chronic Immune Thrombocytopenic Purpura. Seminars in Hematology, 44, S3-S11.
http://dx.doi.org/10.1053/j.seminhematol.2007.11.002

[4]   Thota, S., Kistangari, G., Daw, H. and Spiro, T. (2012) Immune Thrombocytopenia in Adults: An Update. Cleveland Clinic Journal of Medicine, 79, 641-650.
http://dx.doi.org/10.3949/ccjm.79a.11027

[5]   Provan, D. (2009) Characteristics of Immune Thrombocytopenic Purpura: A Guide for Clinical Practice. European Journal of Haematology, 71, 8-12.
http://dx.doi.org/10.1111/j.1600-0609.2008.01207.x

[6]   Anoop, P. (2012) Immune Thrombocytopenic Purpura: Historical Perspective, Current Status, Recent Advances and Future Directions. Indian Pediatrics, 49, 811-818.
http://dx.doi.org/10.1007/s13312-012-0195-1

[7]   Kuwana, M. and Ikeda, Y. (2005) The Role of Autoreactive T-Cells in the Pathogenesis of Idiopathic Thrombocytopenic Purpura. International Journal of Hematology, 81, 106-112.
http://dx.doi.org/10.1532/IJH97.04176

[8]   Cines, D.B., Liebman, H. and Stasi, R. (2009) Pathobiology of Secondary Immune Thrombocytopenia. Seminars in Hematology, 46, S2-S14.
http://dx.doi.org/10.1053/j.seminhematol.2008.12.005

[9]   McCrae, K. (2011) Immune Thrombocytopenia: No Longer “Idiopathic”. Cleveland Clinic Journal of Medicine, 78, 358-373.
http://dx.doi.org/10.3949/ccjm.78gr.10005

[10]   Laboratory Corporation of America, Directory of Services and Interpretive Guide (2010) Platelet Autoantibody Panel, Whole Blood. Platelet Antibody Profile, Serum.
https://www.labcorp.com/wps/portal/

[11]   Laborator Synevo (2010) Referintele specifice tehnologiei de lucru utilizate.
https://www.synevo.ro/anticorpiantitrombocitari-liberi-in-ser/

[12]   Laborator Synevo (2010) Referintele specifice tehnologiei de lucru utilizate.
https://www.synevo.ro/anticorpi-antinucleariana/

[13]   Laborator Synevo (2013) Referintele specifice tehnologiei de lucru utilizate.
https://www.synevo.ro/anticorpi-anti-adn-dublu-catenar/

[14]   Laborator Synevo (2013) Referintele specifice tehnologiei de lucru utili-zate.
http://www.synevo.ro/anticorpi-anticardiolipinici-igg/

[15]   Adam, C. and Douglas, B. (2010) Immune Thrombocytopenia. Hematology, 374-384.

[16]   Ktona, E., Barbullushi, M., Backa, T., Idrizi, A., Shpata, V. and Roshi, E. (2014) Evaluation of Thrombocytopenia in Systemic Lupus Erythematosus and Correlation with Different Organs Damages. Materia Socio Medica, 26, 122-124.
http://dx.doi.org/10.5455/msm.2014.26.122-124

[17]   Wendi, L. (2010) Antiphospholipid Antibody Syndrome. Hematology, 233-239

 
 
Top